ketorolac has been researched along with Pain, Intractable in 5 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Pain, Intractable: Persistent pain that is refractory to some or all forms of treatment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ketorolac can be well tolerated in high-dose, long-term use even in this frail patient population." | 6.69 | The opioid-sparing effects of intravenous ketorolac as an adjuvant analgesic in cancer pain: application in bone metastases and the opioid bowel syndrome. ( Joishy, SK; Walsh, D, 1998) |
| " Ketorolac can be well tolerated in high-dose, long-term use even in this frail patient population." | 2.69 | The opioid-sparing effects of intravenous ketorolac as an adjuvant analgesic in cancer pain: application in bone metastases and the opioid bowel syndrome. ( Joishy, SK; Walsh, D, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dunbar, SA | 1 |
| Karamian, I | 1 |
| Zhang, J | 1 |
| De Conno, F | 1 |
| Zecca, E | 1 |
| Martini, C | 1 |
| Ripamonti, C | 1 |
| Caraceni, A | 1 |
| Saita, L | 1 |
| Middleton, RK | 1 |
| Lyle, JA | 1 |
| Berger, DL | 1 |
| Hughes, A | 1 |
| Wilcock, A | 1 |
| Corcoran, R | 1 |
| Joishy, SK | 1 |
| Walsh, D | 1 |
1 review available for ketorolac and Pain, Intractable
| Article | Year |
|---|---|
Ketorolac continuous infusion: a case report and review of the literature.
Topics: Analgesics, Non-Narcotic; Humans; Infusions, Intravenous; Ketorolac; Male; Middle Aged; Pain, Intrac | 1996 |
2 trials available for ketorolac and Pain, Intractable
| Article | Year |
|---|---|
Ketorolac: continuous subcutaneous infusion for cancer pain.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Dose-Response Relationship, Drug; Drug Adm | 1997 |
The opioid-sparing effects of intravenous ketorolac as an adjuvant analgesic in cancer pain: application in bone metastases and the opioid bowel syndrome.
Topics: Adult; Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Bone Neoplasms; Colonic Ps | 1998 |
2 other studies available for ketorolac and Pain, Intractable
| Article | Year |
|---|---|
Ketorolac prevents recurrent withdrawal induced hyperalgesia but does not inhibit tolerance to spinal morphine in the rat.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Dose-R | 2007 |
Tolerability of ketorolac administered via continuous subcutaneous infusion for cancer pain: a preliminary report.
Topics: Adult; Aged; Analgesics; Female; Humans; Infusions, Parenteral; Ketorolac; Male; Middle Aged; Neopla | 1994 |